Pages that link to "Q43283710"
Jump to navigation
Jump to search
The following pages link to Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials (Q43283710):
Displaying 50 items.
- Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Q24202545) (← links)
- Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Q24234493) (← links)
- Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis (Q26740229) (← links)
- Roflumilast: a review of its use in the treatment of COPD (Q26770501) (← links)
- A rational approach to single, dual and triple therapy in COPD (Q26776477) (← links)
- Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? (Q26777927) (← links)
- Positioning new pharmacotherapies for COPD (Q26798659) (← links)
- The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease (Q26828971) (← links)
- Chronic bronchitis and chronic obstructive pulmonary disease (Q26991702) (← links)
- Clinical issues of mucus accumulation in COPD (Q26992257) (← links)
- PDE4 as a target for cognition enhancement (Q27008296) (← links)
- Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review (Q27015685) (← links)
- Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline (Q27348844) (← links)
- Optimizing management of chronic obstructive pulmonary disease in the upcoming decade (Q27693341) (← links)
- Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis (Q28070108) (← links)
- The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications (Q28081970) (← links)
- Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease (Q28086971) (← links)
- Chronic obstructive pulmonary disease (Q28259151) (← links)
- RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5 (Q28386161) (← links)
- Epidemiology and management of common pulmonary diseases in older persons (Q28397465) (← links)
- The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice (Q28487329) (← links)
- Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis (Q30249747) (← links)
- Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials (Q33498278) (← links)
- Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages (Q33564601) (← links)
- Counterpoint: were industry-sponsored roflumilast trials appropriate? No. (Q33572575) (← links)
- The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma (Q33737175) (← links)
- Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials (Q33824534) (← links)
- A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. (Q33838209) (← links)
- No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study (Q33919207) (← links)
- Influencing the decline of lung function in COPD: use of pharmacotherapy (Q33966001) (← links)
- Advances in targeting cyclic nucleotide phosphodiesterases (Q34139490) (← links)
- Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis (Q34160321) (← links)
- Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma (Q34409716) (← links)
- Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages (Q34475700) (← links)
- The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma (Q34491824) (← links)
- Management of chronic obstructive pulmonary disease beyond the lungs (Q34529777) (← links)
- Vulnerable COPD patients with comorbidities: the role of roflumilast. (Q34566361) (← links)
- Biochanin A, a Phytoestrogenic Isoflavone with Selective Inhibition of Phosphodiesterase 4, Suppresses Ovalbumin‐Induced Airway Hyperresponsiveness (Q34706585) (← links)
- Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets (Q34765802) (← links)
- Metabolomic changes in patients with chronic obstructive pulmonary disease with abnormal Savda syndrome (Q34795376) (← links)
- Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells (Q34920790) (← links)
- Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease (Q35028812) (← links)
- A novel nonhuman primate model of cigarette smoke-induced airway disease (Q35143749) (← links)
- Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population (Q35194591) (← links)
- Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines (Q35538249) (← links)
- Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects (Q35560440) (← links)
- Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio (Q35576638) (← links)
- Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease (Q35617626) (← links)
- Adjunctive Treatment with Rhodiola Crenulata in Patients with Chronic Obstructive Pulmonary Disease--A Randomized Placebo Controlled Double Blind Clinical Trial (Q35670482) (← links)
- Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia (Q35792013) (← links)